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punctuations in the remaining scores and were more prev-
alent in the severe category. The patients with a predomi-
nance of the emotional factor showed a better response at 
the end of follow-up. The established cutoff points allow 
the classification of FM patients by severity, to know the 
prognostic and to predict the response to the treatment.
Keywords Fibromyalgia · Severity · Outcome 
assessment · Questionnaires · Instruments · Subgroups
Introduction
Fibromyalgia (FM) is a syndrome with multiple clinical 
manifestations from various organs and systems and not 
only a clinical picture of chronic pain. Therefore, a proper 
evaluation of FM must include not only pain but its most 
prevalent clinical manifestations, as has recently been rec-
ognized with the new diagnostic criteria based on clinical 
symptoms [1].
The evaluation of the severity in FM patients is still difficult 
since there is no gold standard outcome measure with which 
to compare the clinical manifestations of this syndrome. Now-
adays, multiple questionnaires and other instruments are being 
used to measure the severity of each FM symptom [2].
The Fibromyalgia Impact Questionnaire (FIQ) [3] was 
developed in 1991 to measure the impact of FM and it soon 
became the most generalized tool for evaluating FM patients. 
FIQ offers a total score which allows to evaluate the impact of 
FM in patient life. Later, and following the criterion of pain 
intensity alone, cutoff points were calculated, allowing a clas-
sification of FM severity into mild, moderate and severe [4]. 
However, a classification of patient severity following the 
unique criterion of pain shows a clear bias since most of them 
are classified as severe.
Abstract The aim of this study was to establish the cut-
off points in the Combined Index of Fibromyalgia Severity 
(ICAF) questionnaire which allow classification of patients 
by severity and to evaluate its application in the clinical 
practice. The cutoff points were calculated using the area 
under the ROC curve in two cohorts of patients. Three vis-
its, basal, fourth month and 15th month, were considered. 
The external criterion for grading severity was the number 
of drugs consumed by the patient. Sequential changes were 
calculated and compared. Correlations with drug consump-
tion and comparisons of severity between patients with 
different types of coping were also calculated. Correlation 
between the number of drugs and the ICAF total score was 
significant. Three cutoff points were established: absence 
of Fibromyalgia (FM), <34; mild, 34–41; moderate, 41–50 
and severe, >50, with the following distribution of sever-
ity: absence in 0.4 %, mild in 18.7 %, moderate in 32.5 % 
and severe in 48.4 % of the patients. There were signifi-
cant differences between groups. The treatment under daily 
clinical conditions showed a significant improvement of 
the patients which was maintained at the end of follow-up. 
There was a 17 % reduction in the severe category. The 
patients with more passive coping factor showed highest 
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Recently, we have developed and validated the Com-
bined Index of Fibromyalgia Severity (ICAF, acronym for 
Índice Combinado de Afectación en Fibromialgia) [5, 6], 
a new tool for evaluating FM severity based on its most 
prevalent clinical manifestations. ICAF shows a total score 
of global severity where the higher the total score, the more 
severe are the disease and the consequences in patient life. 
ICAF questionnaire may also provide information about 
emotional, physical and coping aspects of the patient, but 
a classification of patient by severity degrees has not been 
developed so far.
The present study has been designed to establish 
the cutoff points in the total score of ICAF question-
naire based on the hypothesis that the number of drugs 
for treating FM patients may be used as a criterion of 
severity. Subsequently, the calculated cutoff points were 
applied in a cohort of FM patients under daily clinical 
practice conditions to determine the degree of disabil-




In this work, two cohorts of patients were studied.
Cohort 1
In order to determine the cutoff points, we used the origi-
nal cohort of patients from the ICAF study [6]. This 
cohort consisted of 232 patients (F: 228 and M: 4) ful-
filling ACR 1990 criteria for FM [7], with a mean age 
of 47.73 ± 8.61 years. All patients were attended by 
FM specialized clinicians from all around the country. 
Informed consent was signed by patients and the proto-
col was approved by the Ethic and Clinical Investigation 
Committee of Hospital Universitario Gregorio Marañón 
of Madrid. A control group of 110 healthy people was 
also studied.
Cohort 2
The newly established cutoff points were finally evalu-
ated in a second cohort of patients consisting of 246 FM 
consecutive patients (F: 233 and M: 13) with a mean age 
of 48.5 ± 9.8 years. All these patients were attended in a 
specialized clinic under daily clinical practice conditions. 
The ICAF questionnaire was used for evaluating these 
patients in consecutive visits, at the beginning of treat-
ment (V1), at fourth month (V2) and at 15th month (V3) 
of follow-up.
ICAF questionnaire
Briefly, the ICAF is a self-administered questionnaire com-
posed of 59 items about the most common clinical mani-
festations of FM [5]. It calculates a total score in such a 
way that a higher score indicates a more severe disease. It 
also offers four indices: emotional, physical, active cop-
ing and passive coping. The emotional factor stresses the 
role of emotional aspects such as anxiety and depression; 
the physical factor evaluates pain, fatigue, sleep quality and 
functional capacity; the active and passive coping factors 
include different coping strategies by which patients cope 
with the disease. Calculated direct scores are transformed 
into a T scale with a mean of 50 and standard deviation of 
10 related to the sample studied.
Similar to total score, higher scores of factors indicate 
more severity with the exception of active coping factor in 
which higher scores indicates a better way to cope with the 
disease.
In Vallejo et al. [5], the reference percentiles to locate 
the patient with respect to the sample are shown, indicating 
that severity is always related to the sample studied.
The weight of each factor in the calculation of the total 
score is different. The emotional factor constitutes 66 % of 
the total score while physical factor is about 23 %. Coping 
factors have a relative small weight with a 6 % for each of 
them [5].
Measure of severity
Previously, in the construction of the ICAF, scores of the 
different factors and total punctuation were correlated 
with external criteria of FM severity such as the presence 
of trigger points, the results of the six-minute walk test, or 
the labor situation, among others [5]. In this work, we have 
used a different external criterion of severity: the number of 
prescribed drugs a patient is taking for treating the disease. 
The working hypothesis in this study has been that the 
number of drugs acting over nervous system (NS) is related 
to the severity of the disease in the sense that a higher num-
ber of drugs are needed to treat a more severe disease.
The severity based on the number of drugs consumed 
by the patient has been established with the following 
criterion:
Mild: Consumption of NSAID or analgesics only.
Moderate: Consumption of one or two drugs acting over 
NS. The most common combination is an antidepressant 
together with a benzodiazepine or hypnotic drug.
Severe: Consumption of three or more drugs acting over 
NS. New types of drugs are introduced or different anti-
depressants or benzodiazepines are added to the previ-
ous treatment.
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A correlation between the ICAF total score and its fac-
tors and drug consumption was also studied.
The cutoff points based on pain intensity established by 
Bennett et al. [4] were used for calculating the severity of 
the disease in the FIQ.
Statistical analysis
To establish cutoff points in the ICAF, the areas under the 
ROC curves were calculated in cohort 1 of patients. For 
each cutoff point, the best equilibrium between specific-
ity and sensitivity was considered in the context of general 
data.
Correlation between total score and different factors 
with drug consumption was calculated with the Pearson 
correlation test.
Chi-square test was used to compare severity between 
patients with different types of coping.
To compare sequential changes in total score and its fac-
tors along the different visits, an analysis of variance with 
repetitive measures was used. Bonferroni correction was 
used to compare pairs.
Statistical analysis was conducted using SPSS ver-
sion 19. A p value <0.05 was accepted for statistical 
significance.
Results
In cohort 1 of patients, the mean FIQ score was 
71.28 ± 15.34. The distribution of the severity calculated 
with the FIQ was mild in 2.6 %, moderate in 18.5 % and 
severe in 78.9 % of the patients.
Correlation between drug consumption and the ICAF 
total score was significant (r = 0.323; p < 0.001), espe-
cially for drugs acting over NS (r = 0.384; p < 0.001) with 
the exclusion of analgesics and NSAID. Table 1 shows the 
increase in the ICAF total score in relation to the increase 
in the number of drugs acting over NS consumed by the 
patients. Classification of patients by severity related to the 
number of drugs consumed is also shown in Table 1. There 
exists a significant increase in the ICAF total score depend-
ing on severity (mild vs. moderate, p < 0.03; moderate vs. 
severe, p < 0.001).
The first cutoff point was calculated in the total score 
to differentiate patients and controls. The cutoff point was 
established in 34, with a sensitivity of 0.996 and specificity 
of 0.727 (Fig. 1a).
To calculate the second cutoff point to differentiate 
absence of FM from mild severe disease, the considered 
option was to enhance specificity. This cutoff point was 
established in 41 with a sensitivity of 0.944 and a specific-
ity of 0.903 (Fig. 1b).
The third cutoff point to differentiate between mild and 
moderate severity was established in 50, with a sensitivity 
of 0.581 and a specificity of 0.574 (Fig. 1c).
Taking into account these cutoff points, in the ICAF 
total score, the severity of patients with FM may be divided 
into:




The distribution of patients in cohort 1 of patients was: 
absence of FM in 3.4 %, mild in 10.8 %, moderate in 
35.3 % and severe in 50.4 % of the patients.
In cohort 2, the application of the previously calcu-
lated cutoff points at V1 showed the following distribu-
tion: absence of FM in 0.4 %, mild severity in 18.7 %, 
moderate severity in 32.5 % and severe severity 48.4 % 
of the patients (Table 2). There exist significant differ-
ences between groups in all total and factor scores, with the 
exception of the passive coping factor, which is similar in 
moderate and severe categories.
Table 1  Classification of severity, number of drugs acting over nervous system consumed by the patients and ICAF total score
a
 Includes antidepressants, benzodiazepines, hypnotics, anticonvulsants, antipsychotic and antihistaminic, with the exclusion of analgesics (any 
type) and NSAID
No. of  
drugsa




No. of patients (%)  
in the category
ICAF total score
Mean (SD) in the category
Mild 0 61 (26.3) 47.23 (7.86) 61 (26.3) 47.23 (7.86)
Moderate 1 73 (31.5) 48.97 (8.94) 124 (53.5) 50.15 (8.81)
2 51 (22.0) 51.84 (8.42)
Severe 3 29 (12.5) 56.62 (9.95) 47 (20.2) 57.52 (10.53)
4 14 (6.0) 58.70 (12.98)
5 4 (1.7) 59.97 (4.59)
Total 232 (100) 232 (100)
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At visit V2, the treatment under daily clinical practice 
conditions showed a significant improvement of the patients 
(Table 3). The ANOVA performed with the three visits showed 
significant effects in the ICAF total score [F(2,82) = 12.49, 
p < 0.001], emotional factor [F(2,82) = 15.47, p < 0.001] 
and physical factor [F(2,82) = 10.15, p < 0.001], while 
there were no significant effects in the active coping fac-
tor [F(2,82) = 0.72, p < 0.49] or the passive coping factor 
[F(2,82) = 0.09, p < 0.91]. The significant improvement 
obtained at V2 is also maintained at V3 15 months later of 
V1. Means and multiple comparisons are shown in Table 3.
The favorable effect of the treatment throughout time 
produced an evolution of the severity with an increase in 
the less severe categories, as show in Table 4. At V3, there 
was a 17 % reduction in the severe category with a similar 
increase in the less severe categories (absence plus mild).
In the analysis of coping predominance, patients with 
more passive coping factor score, i.e., those who have a 
higher score in the passive coping than in the active cop-
ing factor, showed highest scores in total, emotional and 
physical factors, and may be considered to be worse. 
These patients consume more drugs, specially benzo-
diazepines and antidepressants. The severity in V1 also 
showed a significant prevalence of the severe category 
among the patients with more passive coping strategies (χ2 
(3) = 70.30, p < 0.001) (Table 5).
At V2, the treatment showed a good response in both 
groups of patients with a predominance of the active or the 
passive coping. However, at V2, the analysis of severity 
still showed a significantly worse situation in patients with 
a predominance of passive coping strategies (χ2 (3) = 9.36, 
p = 0.025) (Table 5).
The response to the treatment in patients with a pre-
dominance of the emotional factor or the physical factor 
was similar, with no statistical differences between them at 
V2. However, in the group with a higher score in the physi-
cal factor than in the emotional factor, at V3, there was no 
statistical difference with respect to V1, which indicates a 
lack of response to the treatment. By contrast, the group 
of patients with a higher score in the emotional factor still 
maintained a significant response to the treatment at V3.
Fig. 1  ROC curves
Table 2  Classification by severity in cohort 2 of patients using cutoff 
points at V1
Total and factor scores at V1
Severity
Mild Moderate Severe
No. of patients No. of patients No. of patients
47 (19.1 %) 80 (32.5 %) 119 (48.4 %)
Mean (SD) Mean (SD) Mean (SD)
ICAF total 36.47 (3.61) 46.29 (2.96) 60.21 (6.05)
Emotional 38.53 (4.57) 45.83 (4.95) 60.17 (7.12)
Physical 40.92 (8.57) 50.34 (6.95) 58.10 (6.15)
Active coping 60.61 (5.63) 54.93 (8.53) 46.13 (9.73)
Passive coping 45.06 (8.71) 50.32 10.45) 52.50 (11.86)
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Discussion
The ICAF is a self-administered questionnaire designed for 
the evaluation of multidimensional aspects of FM patients 
[5]. As previously mentioned, it already contains a severity 
reference by assigning the corresponding place in the origi-
nal distribution of patients studied for the development of 
the instrument. This explains the normalized punctuations 
(T score) used in this questionnaire. Also in the development 
of the ICAF, external criteria such as labor status, presence 
of trigger points and six-minute walk test were employed 
for the validation of the punctuation distribution [5].
In the current work, an additional criterion has been 
considered: measuring global severity by the number of 
consumed drugs since it better reflects the overall situa-
tion of the patient compared with the severity based on pain 
intensity.
It is known that in addition to generalized pain in FM 
there exist other relevant clinical manifestations such as 
sleep disorders, fatigue, depression, or anxiety. For this 
reason, it is very common that patients with FM consume 
other drugs acting over NS for treating all those clinical 
manifestations, in addition to analgesics and NSAID to 
alleviate pain.
In this work, we have started with the hypothesis that 
the higher the severity of the disease, the higher number of 
drugs consumed by the patient. This fact has been previ-
ously confirmed by Sánchez et al. [8] who demonstrated 
that economical costs associated with drug treatment in FM 
increase by comorbidity rather than with drugs to allevi-
ate pain. We have considered that our point of view may 
be questionable, but we also believe that this approach may 
help clarify the always difficult aspect of quantifying sever-
ity in FM patients.
In our cohort of patients, distribution of severity after 
applying ICAF calculated cutoff points was 14, 35 and 
50 % for mild, moderate and severe forms, respectively, 
whereas distribution of the severity following the FIQ cut-
off points yielded 3, 18 and 79 %, respectively. As it can be 
seen, the distribution is more normal using the ICAF cutoff 
points with a lesser number of severe forms and a higher 
frequency of mild ones. In the original work by Bennett 
et al. [4] where cutoff points were established for the FIQ, 
the mild forms were only observed in 6 % of the patients.
Our results confirm the initial working hypothesis and 
the calculated cutoff points allow the classification of 
patients in a more practical way than other existing ques-
tionnaires. Classification of the disease in terms of severity 
also allows to establish an overall prognosis. In this work, 
Table 3  Total ICAF and factors score along visits
* p < 0.001, Bonferroni
V1 Mean (SD) V2 Mean (SD) V1–V2 diff. CI 95 % V3 Mean (SD) V1–V3 diff. CI 95 %
ICAF total 51.13 (10.12) 46.73 (10.39) 4.40* 1.98–6.82 46.07 (11.03) 5.06* 2.03–8.09
Emotional 52.86 (10.59) 48.18 (9.85) 4.68* 2.26–7.09 47.40 (10.05) 5.46* 2.52–8.39
Physical 51.14 (9.11) 45.96 (12.70) 5.18* 2.41–7.94 46.33 (12.49) 4.81* 1.71–7.90
Active coping 53.34 (10.09) 53.61 (9.75) −0.27 −2.77–2.24 54.46 (9.40) −1.12 −3.47–1.23
Passive coping 50.70 (11.56) 50.50 (11.26) 0.20 −2.20–2.60 50.24 (11.70) 0.46 −2.49–3.41
Table 4  Evolution of the severity categories along visits
V1 V2 V3
No. of patients 
(%)
No. of patients 
(%)
No. of patients 
(%)
Absence of FM 1 (0.4) 18 (11.3) 12 (13.3)
Mild 46 (18.7) 23 (14.5) 20 (22.2)
Moderate 80 (32.5) 76 (47.8) 30 (33.3)
Severe 119 (48.4) 42 (26.4) 28 (31.1)
Table 5  Severity in patients 
classified by coping strategy 




Active Passive Active Passive
No. of patients (%) No. of patients (%) No. of patients (%) No. of patients (%)
Absence of FM 1 (0.7) 0 14 (15.4 %) 4 (5.9 %)
Mild 45 (33.6) 1 (0.9) 16 (17.6 %) 7 (10.3 %)
Moderate 53 (39.6) 27 (24.1) 44 (48.4 %) 32 (47.1 %)
Severe 35 (26.1) 84 (75.0) 17 (18.7 %) 25 (36.8 %)
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77 % of patients classified as mild still remained with the 
same degree of severity, whereas 50 % still continued to be 
classified as severe 1 year later.
To classify patients by severity also has several impli-
cations in the field of therapeutic decisions and economic 
costs of resource utilization. For those patients classified as 
severe, it seems logical to intensify treatment specially by 
using other therapeutic approaches such as physical exer-
cise programs as well as psychological therapeutic modali-
ties. Incorporating psychoeducational resources in primary 
care may improve therapeutic response and reduce the 
probability of impairment in these patients [9].
The ICAF questionnaire also provides interesting infor-
mation through the different factors in which it is com-
posed. The emotional factor provides the most factorial 
component with respect to the total score and patients 
with higher punctuation in the emotional factor also have 
a higher total score, as it is shown in this work. However, 
these patients also have a good response to the treatment 
and they would be the better candidates for drug treatment, 
especially antidepressants.
A high punctuation in the physical factor is associated 
with a long-term poorer response, as it is shown in our 
results. In this group are included those patients with higher 
degrees of fatigue, closer to chronic fatigue syndrome, 
and it is known that these patients have a poor response to 
pharmacological treatments, especially to antidepressants 
[10]. In this group of patients, exercise programs should 
be emphasized and more sophisticated physiotherapy pro-
grams with well-elaborated adherence strategies may be the 
best therapeutic approach.
Although both coping factors only add a small percent-
age to the ICAF total score, the evaluation of coping strate-
gies is very useful [11]. Indeed, as shown by our results, 
coping factor scores are determinant to determine the sever-
ity of the disease. Patients with high passive coping scores 
have higher total scores, consume more drugs and also 
have a poorer prognostic. Intensifying drug therapy in these 
patients does not seem to be the best strategy since they are 
already taking more drugs than the rest of the patients and 
that does not work properly for them. They need a person-
alized psychotherapeutic intervention or a guided psycho-
logical therapy to improve coping with the disease and to 
reduce the probability of impairment. Alternatively, psy-
chological group therapy or via the Internet has been also 
shown to be useful [12, 13].
In comparison with other FM global outcome indexes, 
the ICAF shows some strengths and some disadvantages. 
As a clear strength, it is remarkable that the ICAF has 
been confronted with external criteria not coming from the 
patient self-report, in contrast with other tools and ques-
tionnaires such as CODI [14], CRSFS [15] or FiRST [16], 
in which no external criteria were used for its construction. 
Another strength is the presence of the two coping fac-
tors, because good coping strategies are very important in 
the favorable outcome in chronic diseases, and the afore-
mentioned questionnaires do not specifically consider such 
aspects.
It is difficult to cover all principal clinical aspects of FM 
with a short questionnaire. Indeed, the ICAF contains 59 
items, while CODI has 26 [14], CRSFS has 20 [15] and 
FiRST has 6 items [16]. Even considering that shortness is 
an important aspect of a questionnaire, it could not be at 
the expense of eliminating basic aspects in the evaluation 
of an FM patient, as it occurs with emotional aspects in the 
FiRST questionnaire [16]. On the other hand, a more com-
plete questionnaire may contribute to clarify some believes 
that general practitioners have about FM [17].
Outcomes measures in FM still remain controversial. 
Recently, the OMERACT has elaborated a report based on 
experts’ opinion about the most important outcome meas-
ures that must be evaluated in patients with FM [18]. How-
ever, an online interview with patients [19] shows that there 
exist some highly valued variables by the patients that are 
not included in the experts inform of OMERACT. A pos-
sible explanation of this divergence between patients and 
experts may be that for some aspects such as stiffness or 
cognitive dysfunction, highly evaluated by the patients, 
there are no effective instruments of measurement, and for 
this reason, the experts do not include them.
In recent clinical trials with drugs for treating FM, the 
most common outcome measure is pain [2]. However, 
pain is just an aspect of the disease and in some patients 
not even the most important clinical manifestation. When 
a clinical trial is designed, if this consideration is not taken 
into account, there may be different populations of FM 
patients with different responses to the same treatment. So, 
a favorable response in the outcome of pain may be misin-
terpreted if the intervention does not improve some of the 
aspects of FM.
The strong point of this study is that results about clas-
sification of severity obtained in a multicentric cohort of 
patients with FM have been well reproduced in a differ-
ent cohort of patients in daily clinical practice showing the 
same useful information.
The principal limitation of this study lies in that the 
ICAF has not been proven in clinical trials and has not been 
compared with other tools. However, if ICAF has shown 
to be sensible to the changes that occur in daily practice 
conditions—both in short and in longer periods of time—
the response will probably be similar under clinical trial 
conditions.
In addition, in this study, we have not established a com-
parison with an untreated control group, and for this reason, 
it is not possible to determine whether changes observed 
throughout time are due to the treatment itself.
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In conclusion, the ICAF has shown to be an excellent 
outcome measure, which allows the classification of FM 
patients by severity in a very practical way, to determine 
the prognostic of the disease and to predict the response 
to the treatment through its different component factors. 
These are all important issues which impact positively on 
usual clinical practice with FM patients, and provide inval-
uable information which is now difficult and time consum-
ing to obtain.
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